Contextualizing the Modern Epidemiology of Neurofibromatosis Type 2 in an Era of Heightened Detection of Sporadic Vestibular Schwannoma

被引:2
作者
Dowling, Eric M. [1 ]
Marinelli, John P. [2 ]
Lohse, Christine M. [3 ]
Carlson, Matthew L. [1 ,4 ]
机构
[1] Mayo Clin, Dept Otolaryngol Head & Neck Surg, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Alix Sch Med, Rochester, MN USA
[3] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA
[4] Mayo Clin, Dept Neurol Surg, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
Acoustic neuroma; Epidemiology; Incidence; Neurofibromatosis type 2; Prevalence; Rochester epidemiology project; Schwannomatosis; Vestibular schwannoma; MEDICAL-RECORDS LINKAGE; TUMOR-PRONE SYNDROMES; SOMATIC MOSAICISM; ACOUSTIC NEUROMA; POPULATION; PREVALENCE; FREQUENCY; DISEASE; RISK; GENE;
D O I
10.1097/MAO.0000000000002557
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective:Closely paralleling previous radiologic studies, recent population-based prevalence data suggest sporadic vestibular schwannoma (VS) affects over one in 2,000 adults and up to one in 500 in those aged 70 years or older. Attributable to increased utilization of magnetic resonance imaging and screening protocols for asymmetrical sensorineural hearing loss, the increasing detection rate of sporadic VS fundamentally changes the perception of VS as a whole. The primary objective of the current study was to contextualize modern epidemiological trends in neurofibromatosis type 2 (NF2) in light of these recent advancements in the understanding of sporadic VS.Study Design:Population-based study.Setting:Olmsted County, Minnesota. Population size on January 1, 2017: 159,689 people.Patients:All patients with NF2 diagnosed between Jan 1, 1966 and Dec 31, 2016, identified using the Rochester Epidemiology Project.Main Outcome Measures:Incidence, prevalence.Results:Six incident cases were identified over the past 50 years. From 1966 to 2016, the age- and sex-adjusted incidence rate was 0.10 per 100,000 person-years. The incidence rate remained at 0.12 over the most recent decade. Five cases met disease prevalence criteria, and the age- and sex-adjusted prevalence of NF2 on Jan 1, 2017 was 3.1 per 100,000 persons. All prevalent cases were women, and the resultant prevalence among women only was 6.0 per 100,000 persons.Conclusions:The modern age- and sex-adjusted incidence rate and prevalence of NF2 is 0.10 per 100,000 person-years and 3.1 per 100,000 persons, respectively. In contrast to trends in incidence rates of sporadic VS over the last half-century, this study demonstrates that the incidence of NF2 has remained relatively stable since 1966. This divergence in epidemiological trends is likely attributed to the nature of NF2, with early clinical manifestations resulting in diagnosis regardless of modern advances, whereas the increased incidence of sporadic VS is heavily influenced by improved detection in a greater population of patients with minimally symptomatic or asymptomatic tumors.
引用
收藏
页码:E501 / E506
页数:6
相关论文
共 50 条
  • [31] Therapy of Sporadic and NF2-Related Vestibular Schwannoma
    Yao, Longping
    Alahmari, Mohammed
    Temel, Yasin
    Hovinga, Koos
    CANCERS, 2020, 12 (04)
  • [32] Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
    Bachir, Suha
    Shah, Sanjit
    Shapiro, Scott
    Koehler, Abigail
    Mahammedi, Abdelkader
    Samy, Ravi N.
    Zuccarello, Mario
    Schorry, Elizabeth
    Sengupta, Soma
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) : 1 - 12
  • [33] Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas
    Wu, CL
    Thakker, N
    Neary, W
    Black, G
    Lye, R
    Ramsden, RT
    Read, AP
    Evans, DGR
    JOURNAL OF MEDICAL GENETICS, 1998, 35 (12) : 973 - 977
  • [34] A clinical study of vestibular schwannomas in type 2 neurofibromatosis
    Kishore, A
    O'Reilly, BF
    CLINICAL OTOLARYNGOLOGY, 2000, 25 (06) : 561 - 565
  • [35] Vestibular schwannoma in a patient with neurofibromatosis type 1: clinical report and literature review
    Huq, Aamira
    Kentwell, Maira
    Tirimacco, Amanda
    Rossini, Jacqueline
    Rawlings, Lesley
    Winship, Ingrid
    FAMILIAL CANCER, 2015, 14 (01) : 157 - 160
  • [36] Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801
    Dougherty, Mark C.
    Shibata, Seiji B.
    Clark, J. Jason
    Canady, Franklin J.
    Yates, Charles W.
    Hansen, Marlan R.
    JOURNAL OF NEUROSURGERY, 2023, 138 (04) : 962 - 971
  • [37] Facial Nerve Outcomes After Vestibular Schwannoma Microsurgical Resection in Neurofibromatosis Type 2
    Sobieski, Catherine
    Killeen, Daniel E.
    Barnett, Samuel L.
    Mickey, Bruce E.
    Hunter, Jacob B.
    Isaacson, Brandon
    Kutz, Joe Walter
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2021, 164 (04) : 850 - 858
  • [38] Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2: clinical results and review of the literature
    Wagner, Johanna
    Welzel, Thomas
    Habermeh, Daniel
    Debus, Juergen
    Combs, Stephanie E.
    TUMORI JOURNAL, 2014, 100 (02): : 189 - 194
  • [39] The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
    Mikkel Christian Alanin
    Camilla Klausen
    Per Caye-Thomasen
    Carsten Thomsen
    Kaare Fugleholm
    Lars Poulsgaard
    Ulrik Lassen
    Morten Mau-Sorensen
    Kenneth Francis Hofland
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 3627 - 3633
  • [40] The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
    Alanin, Mikkel Christian
    Klausen, Camilla
    Caye-Thomasen, Per
    Thomsen, Carsten
    Fugleholm, Kaare
    Poulsgaard, Lars
    Lassen, Ulrik
    Mau-Sorensen, Morten
    Hofland, Kenneth Francis
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2015, 272 (12) : 3627 - 3633